Concepedia

David L. McKinzie

DL

83

Publications

6.6K

Citations

45

H-Index

1992

Active since

Affiliations

Eli Lilly (United States)(Current)

Indiana University – Purdue University Indianapolis

Indiana University School of Medicine

University of Indianapolis

Binghamton University

David L. McKinzie is an author at Eli Lilly (United States) specializing in medicine, neuropharmacology, and social sciences.

ORCID

Top concepts

Publications per year

1992–2022

83

Publications

83

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

Anantha Shekhar, William Z. Potter, Jeffrey Lightfoot et al. · American Journal of Psychiatry · 2008 · 555 citations

Diverse Psychotomimetics Act Through a Common Signaling Pathway

Per Svenningsson, Eleni T. Tzavara, Robert Carruthers et al. · Science · 2003 · 312 citations

Cholinergic dilation of cerebral blood vessels is abolished in M <sub>5</sub> muscarinic acetylcholine receptor knockout mice

Masahisa Yamada, Kathryn G. Lamping, Alokesh Duttaroy et al. · Proceedings of the National Academy of Sciences · 2001 · 273 citations · Full text

3-(4-Chloro-2-Morpholin-4-yl-Thiazol-5-yl)-8-(1-Ethylpropyl)-2,6-Dimethyl-Imidazo[1,2-<i>b</i>]Pyridazine: A Novel Brain-Penetrant, Orally Available Corticotropin-Releasing Factor Receptor 1 Antagonist with Efficacy in Animal Models of Alcoholism

Donald R. Gehlert, Andrea Cippitelli, Annika Thorsell et al. · Journal of Neuroscience · 2007 · 242 citations · Full text

, , +20

Allosteric modulation of the muscarinic M <sub>4</sub> receptor as an approach to treating schizophrenia

Wai‐Yee Chan, David L. McKinzie, Suchira Bose et al. · Proceedings of the National Academy of Sciences · 2008 · 233 citations · Full text

Rows per page

1–5 of 83